FM-479|CAS 2226521-64-6|DC Chemicals

Cas No.:	2226521-64-6
Chemical Name:	(E)-2-Cyano-3-[5-(3-cyclohexyl-10-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]-N,N-dimethylprop-2-enamide
Synonyms:	BCP32593;FM 479;FM479;(E)-2-Cyano-3-[5-(3-cyclohexyl-10-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-penta
SMILES:	N#CC(\C(=O)N(C)C)=C/C1OC(=CC=1)C2N(C3CCCCC3)C4C5=C(N=CC=4N=2)N(C)C=C5
Formula:	C₂₅H₂₆N₆O₂
M.Wt:	442.5129
Purity:	98%
Sotrage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Description:	FM-479 is the negative control of FM-381 (HY-102046) and has no activity on JAK3 or other kinases[1]. FM-381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.
Target:	JAK3
In Vitro:	FM-479 is the inactive control of FM-381, the concentration used in assays is similar[1].

Cat. No.	Product name	Field of application
DC73569	Lepzacitinib (ATI-1777)	Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases.
DC72210	NDI-034858(Zasocitinib)	NDI034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM.
DC72043	VVD-118313	VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer.
DC70831	TD-1473	TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2.TD-1473 inhibited cytokine-induced phosphorylation of STAT1 in mouse primary colonic epithelial cells with pIC50 values for inhibition against IL-6, IFNα and IFNγ were 7.3, 6.8 and 7.0.TD-1473 demonstrated JAK inhibitory activity in ex vivo mouse colon and human IBD patient colonic tissue. TD-1473 (Izencitinib) is under development for the treatment of ulcerative colitis.
DC70233	Londamocitinib（AZD4604）	AZD4604 (AZD-4604) is a potent, selective Janus-associated kinase 1 (JAK1) inhibitor with anti-inflammatory effect.
DC47591	JAK-IN-14	JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).
DC47132	JAK1-IN-8	JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1.
DC47066	Ifidancitinib	Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.
DC47038	Fosifidancitinib	Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.
DC47030	Ilunocitinib	Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).